While there is no therapy available for geographic atrophy (dry AMD), the neovascular (wet) form of AMD is treated by vascular endothelial growth factor (VEGF)-targeting therapies to slow disease progression [7–9]. Here, VEGFA is linked to atrophic macular degeneration.